Last checked at 2 Jun 2014 07:00
For immediate release 07.00: 2 June 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
INVESTOR EVENT
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO human challenge models of disease, is pleased to announce that it will host an investor event on Wednesday 4 June 2014.
The event will open at 16.30 GMT in the auditorium at the Queen Mary BioEnterprises Innovation Centre (42 New Road, London, E1 2AX). The meeting will be hosted by Kym Denny, Chief Executive of Retroscreen, and will include presentations from the Company's hVIVO research team. The presentations will commence at 17.00 and will conclude at 18.30.
The event is intended to provide further insight into Retroscreen's innovation strategy. No material new information on current trading or future financial performance will be disclosed in these presentations.
As capacity is limited, please contact James Black at Numis to register your interest in the event.
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life sciences company pioneering a technology platform called hVIVO which uses human models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled environment.
Retroscreen has established itself as the world leader in this field through the provision of clinical services to third party study sponsors. To date, the Company has conducted over 35 clinical studies, involving more than 1600 volunteers for a range of leading industry, governmental and academic clients.
However, Retroscreen's hVIVO platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.